|3.||Acquired Immunodeficiency Syndrome (AIDS)
|1.||Walsh, Thomas J: 27 articles (12/2015 - 05/2002)|
|2.||Filler, Scott G: 16 articles (05/2015 - 08/2002)|
|3.||Netea, Mihai G: 16 articles (03/2015 - 04/2002)|
|4.||Clancy, Cornelius J: 14 articles (10/2015 - 10/2003)|
|5.||Nguyen, M Hong: 12 articles (10/2015 - 10/2003)|
|6.||Cassone, Antonio: 12 articles (08/2014 - 01/2002)|
|7.||Kullberg, Bart Jan: 12 articles (08/2011 - 04/2002)|
|8.||Han, Yongmoon: 11 articles (11/2013 - 03/2005)|
|9.||Cheng, Shaoji: 11 articles (05/2013 - 10/2003)|
|10.||Gaffen, Sarah L: 10 articles (10/2015 - 02/2009)|
|1.||Fluconazole (Zonal)FDA LinkGeneric
04/01/1990 - "In summary, fluconazole was most effective against disseminated candidiasis in persistently granulocytopenic rabbits when used for prevention or early treatment."
04/01/1990 - "Fluconazole was most effective when used for preventive or early treatment of acute and subacute disseminated candidiasis. "
10/01/2011 - "In the treatment of oropharyngeal candidiasis, E1210 and fluconazole each caused a significantly greater reduction in the number of oral CFU than the control treatment (P < 0.05). "
08/01/1991 - "Fluconazole is a safe and effective agent with significant activity against chronic disseminated candidiasis."
11/01/1990 - "The convenience, good tolerance and clinical efficacy of fluconazole make it the therapy of choice for oropharyngeal candidiasis in immunologically compromised patients."
|2.||Amphotericin B (Amphotericin)FDA LinkGeneric
06/01/2003 - "Gargling with amphotericin B was effective in most asthmatic patients with candidiasis. "
04/01/1989 - "Local application of amphotericin B and donor leukocytic mass was found the most effective in the combined treatment of candidiasis of the esophagus."
05/01/2003 - "In a neutropenic murine model of disseminated candidiasis, kidney colony-forming unit determination revealed dose-dependent efficacy for the polymeric micelle/AmB formulation, which was not significantly different from that of Fungizone at doses of 0.2, 0.3, and 0.6 mg/kg (p = 0.7). "
12/01/2002 - "Intravenous amphotericin B has been found to be effective in azole-refractory candidiasis and is well tolerated. "
06/01/2000 - "Mild heating of amphotericin B-desoxycholate: effects on ultrastructure, in vitro activity and toxicity, and therapeutic efficacy in severe candidiasis in leukopenic mice."
|3.||Itraconazole (Sporanox)FDA LinkGeneric
12/01/2007 - "It is concluded that the efficacy of itraconazole in the treatment of the vaginal candidiasis under different immunity conditions (groups A, E and F) in mice were all good, but there was no difference in the anti-fungal effect of itraconazole among the three groups."
11/01/1995 - "Early oral itraconazole is effective in disseminated candidiasis and well tolerated by children."
04/01/2009 - "These studies suggested that bioadhesive vaginal film is a novel approach for delivery of itraconazole as topical drug delivery system for treating vaginal candidiasis."
06/01/2000 - "Mucosal Candida sp. isolates were obtained from subjects who developed oropharyngeal or esophageal candidiasis, and in vitro susceptibilities of the last isolate obtained at removal from the study as a prophylaxis failure were compared in itraconazole and placebo recipients. "
01/01/1993 - "Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis."
|4.||Ketoconazole (Nizoral)FDA LinkGeneric
03/01/1990 - "Ketoconazole was effective in controlling symptoms of candidiasis in most patients. "
02/01/1985 - "Ketoconazole has been shown to be effective in the treatment of mucocutaneous candidiasis with a reported 97% positive response rate. "
06/01/1983 - "Although the therapeutic efficacy of ketoconazole was demonstrated for oropharyngeal candidiasis, the magnitude of its efficacy was less than that desired."
08/01/1979 - "The efficacy of a new, orally active antimycotic, ketoconazole, in the treatment of vaginal candidiasis was studied at different doses involving 63 patients. "
06/01/1983 - "A double-blind, placebo-controlled study was undertaken to determine the efficacy of ketoconazole in the treatment of candidiasis. "
|5.||caspofungin (Cancidas)FDA Link
01/01/2001 - "Caspofungin was effective in patients with oropharyngeal or oesophageal candidiasis, according to the preliminary results of 2 randomised double-blind trials. "
07/01/2011 - "Efficacy of caspofungin in a juvenile mouse model of central nervous system candidiasis."
04/01/2011 - "Efficacy of a single 6 mg/kg versus two 3 mg/kg caspofungin doses for treatment of disseminated candidiasis caused by Candida albicans in a neutropenic mouse model."
02/01/2002 - "Caspofungin provided a generally well-tolerated parenteral therapeutic option for HIV-infected patients with oropharyngeal and/or esophageal candidiasis in this study."
08/15/2013 - "Paradoxical effect to caspofungin in Candida species does not confer survival advantage in a Drosophila model of candidiasis."
|6.||micafungin (FK463)FDA Link
12/01/2015 - "Intermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits."
04/01/2009 - "Efficacy of micafungin in treating four premature infants with candidiasis."
03/01/2000 - "The efficacy of FK463 was also evaluated in the disseminated candidiasis target organ assay and was compared with those of FLCZ and AMPH-B. "
12/01/2015 - "To improve quality of life, reduce costs, and improve outcome, we studied the pharmacokinetics (PK), efficacy, and safety of alternate dosing regimens of micafungin (MFG) for the treatment of experimental subacute disseminated candidiasis. "
03/01/2015 - "For micafungin, AUC-to-minimum inhibitory concentration (AUC/MIC) ratios have a close deterministic relationship with efficacy in candidiasis; an AUC/MIC ≥3,000 is associated with 98% efficacy. "
01/01/2009 - "Results of several clinical trials indicate that anidulafungin is effective in treating oesophageal candidiasis, including azole-refractory disease. "
07/15/2006 - "Results of several clinical trials indicate that anidulafungin is effective in treating esophageal candidiasis, including azole-refractory disease. "
07/01/2008 - "A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis."
08/01/2009 - "Our data suggest that the efficacy of anidulafungin in the treatment of candidiasis might stem from both direct fungicidal activity and indirect PAFEs that lessen the ability of Candida cells to establish invasive disease and to persist within infected hosts."
07/01/2008 - "We performed an open-label, noncomparative study to examine efficacy and safety of anidulafungin in patients with azole-refractory oropharyngeal and esophageal candidiasis. "
02/17/2010 - "A beta-glucan-conjugate vaccine and anti-beta-glucan antibodies are effective against murine vaginal candidiasis as assessed by a novel in vivo imaging technique."
05/01/2002 - "Intravaginal and intranasal immunizations are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis."
01/01/2012 - "To confirm that induced antibodies were protective, sera from mice immunized against the β-(Man)(3)-Fba-TT conjugate transferred protection against disseminated candidiasis to naïve mice, whereas C. "
08/01/2008 - "However, the potential protective effects of hsp90-CA-specific antibodies in vaginal candidiasis has not yet been reported. "
01/01/2013 - "Nevertheless recent evidence demonstrates that antibodies with defined specificities could act with different degrees showing protection against systemic and mucosal candidiasis. "
|9.||Nystatin (Mycostatin)FDA LinkGeneric
04/15/1978 - "[Case of pulmonary candidiasis treated successfully with nystatin administered orally and in inhalations]."
01/01/2008 - "Here, we studied the efficacy of a commercially available topical Nystatin suspension in a new ex-vivo model of candidiasis using porcine oral mucosa. "
10/01/1999 - "Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits."
05/01/1994 - "However, up to now, no study has correctly assessed the value of nystatin as a prophylactic agent against oropharyngeal candidiasis."
07/01/1959 - "[Chemotherapeutic studies on nystatin in experimental candidiasis in white mice]."
|10.||Clotrimazole (Lotrimin)FDA LinkGeneric
01/01/1984 - "The findings indicate that a single 500-mg tablet of clotrimazole is effective and safe in the treatment of vaginal candidiasis and suggest that the efficacy and safety of the one-dose regimen are comparable to those of more prolonged courses with the 100-mg tablet of clotrimazole. "
11/01/1986 - "Clotrimazole is effective in preventing oropharyngeal candidiasis."
07/01/1974 - "A preliminary report on a trial of clotrimazole against vaginal candidiasis in venereology."
07/01/1974 - "An open trial of local therapy with clotrimazole for vaginal candidiasis."
07/01/1974 - "Vaginal candidiasis in pregnancy--a trial of clotrimazole."
|1.||Transplantation (Transplant Recipients)
07/01/2005 - "The study included 17 hematopoietic stem cell transplant recipients with proved pulmonary candidiasis. "
11/01/2015 - "Donor-derived candidiasis has been described in kidney transplant recipients where contamination of the preservation fluid (PF) was a commonly proposed source. "
01/01/2014 - "The persistence of biliary candidiasis is associated with markedly reduced transplantation-free survival in PSC patients. "
09/01/2012 - "Most cases of donor-derived candidiasis have occurred in kidney transplant recipients in whom contaminated preservation fluid is a commonly proposed source. "
05/01/2006 - "The incidence of esophageal and urogenital candidiasis in kidney and kidney-pancreas transplant recipients has not been well documented. "
|2.||Highly Active Antiretroviral Therapy (HAART)
12/01/2012 - "Because of the frequently marked and prompt immune reconstitution induced by HAART, there is no recommendation for primary antifungal prophylaxis of mucosal candidiasis in the HIV setting in Europe, although it has been evidenced as effective in the pre-HAART era. "
08/01/2005 - "Colonization did not correlate with CD4+ number or viral load, but highly active antiretroviral therapy reduced the frequency of candidiasis. "
02/01/2015 - "The advent of highly active antiretroviral therapy (HAART) has changed the epidemiology of candidiasis, with many studies reporting a decrease in prevalence. "
09/01/2013 - "The study confirmed that the incidence of oral lesions and of pseudo-membranous candidiasis in particular, were statistically significantly reduced in patients receiving HAART."
01/01/2013 - "The aim of our study was to estimate the candidiasis rate and evaluate its trend in HIV-infected children in Spain during the era of highly active antiretroviral therapy (HAART) compared to HIV-uninfected children. "
02/15/2002 - "In this study, beige-athymic (bg/bg-nu/nu) or transgenic epsilon 26 mice that have combined natural killer and T cell defects did not succumb to candidiasis after oral administration of C. "
02/01/1993 - "Candidiasis was experimentally produced in young Japanese quail by oral administration of Candida albicans cells. "
02/01/2007 - "Oral administration of itraconazole OS displayed therapeutic efficacy against murine oral and oesophageal candidiasis superior to that achieved by intragastric administration. "
02/01/2007 - "In the oesophageal candidiasis model, oral administration of itraconazole OS displayed superior therapeutic efficacy to the intragastric route. "
02/01/2007 - "Oral administration of itraconazole solution has superior efficacy in experimental oral and oesophageal candidiasis in mice than its intragastric administration."
03/01/1999 - "Before the appearance of these reports, the best results were obtained with removal of the catheter in renal candidiasis."
08/01/2012 - "[Could antifungal lock be useful in the management of candidiasis linked with catheters?]."
07/01/2015 - "Consequently, control and treatment of vaginal candidiasis as a means to prevent biofilm formation on urinary catheters is of crucial importance."
01/01/2014 - "Prophylactic thrombolysis should be encouraged to prevent central venous catheter-related candidiasis in clinical practice."
07/01/2004 - "Independent risk factors for disseminated candidiasis were persistently positive blood cultures for Candida (>3 days) with a central venous catheter in place (odds ratio, 3.0; 95% confidence interval, 1.2, 7.8; P = 0.02) and immunosuppression (odds ratio, 2.9; 95% confidence interval, 1.2, 7.0; P = 0.02). "
|5.||Drug Therapy (Chemotherapy)
08/01/2006 - "Studies were done to develop a murine model that mimics the pattern of mucosal candidiasis followed by disseminated disease seen in patients given cytotoxic chemotherapy. "
01/01/2015 - "Whereas, for preventing spread of the disease to deeper vital organs, candidiasis antifungal chemotherapy is preferred. "
05/01/2014 - "Shorter times and lower energies of application of light sources are desirable to use photodynamic antimicrobial chemotherapy (PACT) to the clinical control of candidiasis, especially among babies and children. "
09/01/2007 - "In the recent years, there has been a marked increase in the incidence of treatment failures in candidiasis patients receiving long-term antifungal therapy, which has posed a serious problem in its successful use in chemotherapy. "
11/01/2006 - "Systemic and hepatosplenic candidiasis have been reported in acute leukemic patients who are on chemotherapy. "